Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19
Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2024.2418798 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716261581225984 |
|---|---|
| author | Sara Samir Mohamed Elmenshawy Mohamed Farouk Ahmed Abdelsalam Tarek Refaat El Nagdy Mohamed Abdel Salam Elgohary Nagwa Ali Sabri Amal El-kholy |
| author_facet | Sara Samir Mohamed Elmenshawy Mohamed Farouk Ahmed Abdelsalam Tarek Refaat El Nagdy Mohamed Abdel Salam Elgohary Nagwa Ali Sabri Amal El-kholy |
| author_sort | Sara Samir Mohamed Elmenshawy |
| collection | DOAJ |
| description | Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462. |
| format | Article |
| id | doaj-art-9f12e12c9a5c460abb2f790331cb5de1 |
| institution | DOAJ |
| issn | 2056-5623 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-9f12e12c9a5c460abb2f790331cb5de12025-08-20T03:13:04ZengTaylor & Francis GroupFuture Science OA2056-56232024-12-0110110.1080/20565623.2024.2418798Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19Sara Samir Mohamed Elmenshawy0Mohamed Farouk Ahmed Abdelsalam1Tarek Refaat El Nagdy2Mohamed Abdel Salam Elgohary3Nagwa Ali Sabri4Amal El-kholy5Clinical Pharmacist, Al-Galaa Military Medical Complex, Cairo, EgyptConsultant of Clinical Pharmacology & Clinical Nutrition, Al-Galaa Military Medical Complex, Cairo, EgyptECRRM Egypt Center for Research & Regenerative Medicine, Cairo, EgyptTropical Medicine Military Medical Academy, Cairo, EgyptClinical Pharmacy-Clinical Pharmacy Department-Faculty of Pharmacy-Ain Shams University, Cairo, EgyptClinical Pharmacy-Clinical Pharmacy Department-Faculty of Pharmacy-Ain Shams University, Cairo, EgyptAim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462.https://www.tandfonline.com/doi/10.1080/20565623.2024.2418798Coronavirus disease 2019COVID-19CT-scandyspneafeveroseltamivir |
| spellingShingle | Sara Samir Mohamed Elmenshawy Mohamed Farouk Ahmed Abdelsalam Tarek Refaat El Nagdy Mohamed Abdel Salam Elgohary Nagwa Ali Sabri Amal El-kholy Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 Future Science OA Coronavirus disease 2019 COVID-19 CT-scan dyspnea fever oseltamivir |
| title | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 |
| title_full | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 |
| title_fullStr | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 |
| title_full_unstemmed | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 |
| title_short | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 |
| title_sort | evaluation of the efficacy of triazavirin versus oseltamivir in management of covid 19 |
| topic | Coronavirus disease 2019 COVID-19 CT-scan dyspnea fever oseltamivir |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2024.2418798 |
| work_keys_str_mv | AT sarasamirmohamedelmenshawy evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 AT mohamedfaroukahmedabdelsalam evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 AT tarekrefaatelnagdy evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 AT mohamedabdelsalamelgohary evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 AT nagwaalisabri evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 AT amalelkholy evaluationoftheefficacyoftriazavirinversusoseltamivirinmanagementofcovid19 |